Introduction
============

Hepatitis C virus (HCV) represents a major public health burden in both industrialized and developing countries. The prevalence of HCV infection is estimated to be 2.2-3.0% (130-170 million people) worldwide \[[@B1]\]. Region-specific estimates range from \< 1.0% in Northern Europe to \> 2.9% in Northern Africa, with the highest prevalence (15%-20%) reported in Egypt \[[@B2]\]. About 15 to 20% of HCV infections progress to potentially serious cirrhosis and end-stage liver disease \[[@B3]\]. Due to shared mode of transmission, co-infection of HCV and human immunodeficiency virus (HIV) has become a growing public health concern. Among the estimated 40 million individuals infected with HIV worldwide, about 4-5 million are chronically infected with HCV \[[@B4]\]. Prevalence and mode of transmission of each of the two viral infections are the main determinants of co-infection rate, and vary according to the geographic region. For instance, co-infection is high in patients that acquire the viruses through parenteral routes compared with those infected through sexual route \[[@B5]\].

In Ethiopia, a previous population-based survey had reported a moderate prevalence (2%) of HCV infection \[[@B6]\]. However, information is scarce regarding the rate of HIV-HCV co-infection in our setting where HIV is prevalent. This study was conducted to describe the prevalence and risk factors for HCV infection in people with and without HIV infection.

Methods
=======

A sero-prevalence study of HCV was conducted in people with and without HIV infection attending HIV testing centers (Hawassa Referral Hospital, Hawassa Health Centre, Organization for Social Services for AIDS (OSSA), and Beth-Zeta Hospital) from October to December, 2008. These centers are located in Hawassa, the capital city of the Southern Nations, Nationalities and Peoples\' Regional State and one of the administrative regions in Ethiopia. The centers provide voluntary HIV counseling and testing services using two approaches: a client-initiated approach to serve people seeking to know their HIV status, and a provider-initiated approach which enables health care provider offer targeted medical services. Clients who are tested HIV positive are usually referred to the Hawassa Referral Hospital. Clinical and immunological assessments (CD4+ T cell count) at enrollment and at six-monthly follow-up visits identify those who are eligible for anti-retroviral therapy (ART). Those receiving ART monitor their disease status on a regular basis. Services including HIV counselling and testing, clinical and immunological assessments as well as ART are provided free of charge.

In this study, consecutive HIV-positive individuals who were at their first enrollment at the ART clinic as well as those who had been receiving ART for at least six months were recruited prospectively. Consecutive clients, who were tested HIV negative at any of the centers during the study period, were recruited for comparative purposes. The sample size was estimated using HCV prevalence rates of 4.5% and 0.8% in HIV-positive and HIV-negative subjects, respectively \[[@B7]\]. With 95% level of confidence and 80% power of the study, the required sample size would be 800 (400 individuals in each HIV sero-group). In both HIV sero-groups, only individuals aged 15 years and above were included. Among HIV-positive clients, those found with a CD4+ T cell counts below 50 cells/mm^3^were excluded from the study due to the unreliability of HCV serological tests in a state of severe immunosuppression \[[@B8]\].

Counsellor nurses interviewed the study subjects using structured questionnaires on socio-demographic characteristics and risk factors of HCV infection such as history of traditional and modern medical practices, sexual practices, history of sexual transmitted infections (STIs), liver disease, and family history of liver disease. Remaining sera left from HIV testing and CD4+ T cell measurement were stored at -80°C for the purpose of HCV testing. All sera were screened at the Hawassa Referral Hospital laboratory for HCV antibody (anti-HCV) using Enzyme Linked Immunosorbent Assay (ELISA) (HUMAN anti-HCV ELISA, Germany). Sera found to be positive for anti-HCV were transferred in cold boxes to the International Clinical Laboratories in Addis Ababa where testing for viral ribonucleic acid (RNA) using real-time polymerase chain reaction (PCR) (Abbott RealTi*m*e™ HCV) was performed. According to the manufacturer\'s guidelines, the real-time PCR test has detection sensitivity of a viral load as low as 12 IU/ml of serum. All samples were tested in accordance with the manufacturer\'s instructions and in duplicates to ensure reproducibility. Despite the possibility that the ELISA test introduces false positive result, we interpreted a positive anti-HCV test as HCV-exposure. Presence of HCV-RNA indicates active viral replication.

Data entry and analysis were performed using SPSS Version-16. Descriptive summary was presented in terms of mean, range, and proportions depending on the scale of the variable. Pearson\'s Chi-square test was used to assess differences in proportion of anti-HCV marker between HIV-infected and HIV**-**non-infected individuals. The strength of association between HCV status and risk factors was measured by calculating odds ratios. A given statistical test was reported significant whenever it resulted in a p-value \< 0.05.

The study was approved by the Ethics Committees of Aklilu Lemma Institute of Pathobiology, Addis Ababa University and the College of Medicine and Health Sciences, Hawassa University. All participants gave informed written consent, and doctors managed HCV-positive cases.

Results
=======

Of the 402 HIV-positive and 404 HIV-negative individuals approached during the study period, 2 HIV-positive and 4 HIV-negative participants were excluded due to insufficient blood volume and refusal, respectively. The majority (94.7%) of HIV-infected participants were urban dwellers and married (48%) (Table [1](#T1){ref-type="table"}). The mean age of HIV-infected participants was 31.7 years (range 18-70 years; SD 8.4) compared with 26.6 years (range 16-62 years; SD 7.3) in HIV**-**non**-**infected clients. The male to female ratio was 0.6:1 in HIV-positive and 0.9:1 in HIV-negative clients. Two-hundred (50%) HIV-infected participants were receiving ART.

###### 

Socio-demographic characteristics of HIV-positive and HIV-negative individuals at Hawassa HIV testing centers, 2008

  Characteristics                       HIV positive (%)   HIV negative (%)   Total (%)
  ------------------------------------- ------------------ ------------------ ------------
  Residence                                                                   
   Rural                                21 (5.3)           17 (4.2)           38(4.8)
   Urban                                379 (94.7)         383(95.8)          762(95.2)
  Sex                                                                         
   Male                                 151(37.8)          191(47.8)          342 (42.8)
   Female                               249 (62.2)         209(52.2)          458 (57.2)
  Age (years)                                                                 
   \<20                                 6(12.5)            42(87.5)           48 (6)
   20-29                                164(40.5)          241(59.5)          405 (50.6)
   30-39                                161(63.6)          92(36.4)           253 (31.6)
   40-49                                55(75.3)           18(24.7)           73 (9.1)
   ≥50                                  14(66.7)           7(33.3)            21 (2.6)
  Marital status                                                              
   Married                              192(48)            97(24.2)           289 (36.1)
   Single                               60(15)             274(68.5)          334 (41.8)
   Divorced                             60(15)             20(5.0)            80 (10 )
   Widowed                              88(22)             9(2.2)             97 (12.1)
  Religion                                                                    
   Orthodox                             250(62.5)          163(40.8)          413 (51.6)
   Protestant                           112(28.0)          199(49.8)          311 (38.9)
   Muslim                               31(7.8)            37(9.2)            68 (8.5)
   Other                                7(1.8)             1(0.2)             8(1.0)
  Educational status Educational stat                                         
   Illiterate                           57(14.2)           19(4.8)            76 (9.5)
   Primary school                       169(42.2)          72(18.0)           241 (30.1)
   Secondary school                     150(37.5)          139(34.8)          289 (36.1)
   Diploma                              16(4.0)            119(29.8)          135 (16.9)
   Degree                               8(2)               51(12.8)           59 (7.4)

The prevalence of anti-HCV in HIV-positive individuals was 10.5% compared to 6% in HIV-negative individuals (p = 0.002) (Table [2](#T2){ref-type="table"}). A comparable rate of anti-HCV marker was observed in HIV-infected individuals with or without ART. HCV- RNA was detected in 6 (9.1%) of all 66 anti-HCV positive samples and viral load ranged from 31 IU/ml - 4.294 million IU/ml of serum. Rate of HCV- RNA was similar among anti-HCV- positive participants with or without HIV infection (7.1% versus 12.5%, respectively; p = 0.39), and in those HIV-infected with or without ART (5.3% versus 8.7%, respectively; p = 0.43).

###### 

Distribution of anti-HCV and HCV-RNA in HIV-positive and HIV-negative individuals at Hawassa HIV testing centers, 2008

  HCV Marker   Total tested   Number (%) positive   HIV-positive   HIV-negative                                             
  ------------ -------------- --------------------- -------------- -------------- ----- ----------- ----- ----------- ----- ----------
  Anti-HCV     800            66 (8.2)              200            19 (9.5)       200   23 (11.5)   400   42 (10.5)   400   24 (6)
  HCV-RNA      66             6 (9.1)               19             1 (5.3)        23    2 (8.7)     42    3 (7.1)     24    3 (12.5)

The exposure of HIV-infected and HIV**-**non**-**infected participants to different risk factors for HCV infection is summarised in Table [3](#T3){ref-type="table"}. Histories of ear piercing and tooth extraction were the most frequently reported exposures in both HIV sero-groups. Among females with HIV infection, 22.5% reported having a history of abortion. Sero- prevalence rate of anti-HCV was higher in HIV-infected participants who reported having multiple sexual partners. There was no significant difference in odds of HCV infection in participants with and without HCV risk factors in either HIV sero-group (Table [3](#T3){ref-type="table"}).

###### 

Anti-HCV positivity in relation to HCV risk factors in HIV-positive and HIV- negative individuals at Hawassa HIV testing centers, 2008

  Characteristics                              HIV-positive   HIV-negative                                             
  -------------------------------------------- -------------- -------------- ------------------ ------------ --------- -----------------
  Hospital admission                                                                                                   
   No                                          300(75.0)      35(11.7)       1                  342 (85.5)   21(6.1)   1
   Yes                                         100(25.0)      7(7.0)         0.57(0.25-1.33)    58 (14.5)    3(5.2)    .83(0.24-2.89)
  Blood transfusion                                                                                                    
   No                                          388(97.0)      41(10.6)       1                  398(99.5)    24(6.0)   
   Yes                                         12(3.0)        1(8.3)         0.77(0.10-6.11)    2(0.5)       0         \-
  Unsafe injection                                                                                                     
   No                                          375(93.8)      40(10.7)       1                  384(96.0)    24(6.2)   
   Yes                                         25(6.2)        2(8.0)         0.73(0.17-3.20)    16(4.0)      0         \-
  Multiple sexual partners \*                                                                                          
   No                                          315(78.8)      31(9.8)        1                  344(86.0)    18(5.2)   1
   Yes                                         85(21.2)       11(12.9)       1.3(0.65-2.84)     56(14.0)     6(10.7)   2.1(0.82-5.74)
  Sexual transmitted infections \*\*                                                                                   
   No                                          282(70.5)      26(9.2)        1                  380(95.0)    23(6.1)   1
   Yes                                         118(29.5)      16(13.6)       1.54(0.80-3.0)     20(5.0)      1(5.0)    0.82(0.11-6.38)
  Tooth extraction                                                                                                     
   No                                          278(69.5)      27(9.7)        1                  286(71.5)    18(6.3)   1
   Yes                                         122(30.5)      15(12.3)       1.30(0.67-2.55)    114(28.5)    6(5.3)    0.83(0.32-2.14)
  Catheterization                                                                                                      
   No                                          393(98.2)      41(10.4)       1                  399(99.8)    24(6.0)   \-
   Yes                                         7(1.8)         1(14.3)        1.43(0.17-12.18)   1(0.2)       0         
  Scarification                                                                                                        
   No                                          373(93.2)      39(10.5)       1                  367(91.8)    23(6.3)   1
   Yes                                         27(6.8)        3(11.1)        1.07(0.31-3.72)    33(8.2)      1(3.0)    0.47(0.06-3.58)
  Abortion                                                                                                             
   No                                          193(77.5)      18(9.3)        1                  195(93.3)    11(5.6)   1
   Yes                                         56(22.5)       7(12.5)        1.39(0.55-3.51)    14(6.7)      1(7.1)    1.29(0.15-10.8)
  Ear piercing                                                                                                         
   No                                          240(60.0)      22(9.2)        1                  292(73.0)    16(5.5)   1
   Yes                                         160(40.0)      20(12.5)       1.42(0.74-2.69)    108(27.0)    8(7.4)    1.38(0.57-3.32)
  Surgery \*\*\*                                                                                                       
   No                                          376(94.0)      40(10.6)       1                  388(97.0)    24(6.2)   
   Yes                                         24(6.0)        2(8.3)         0.76(0.17-3.37)    12(3.0)      0         \-
  Blood letting                                                                                                        
   No                                          390(97.5)      41(10.5)       1                  398(99.5)    24(6.0)   
   Yes                                         10(2.5)        1(10.0)        0.95(0.12-7.66)    2(0.5)       0         \-
  Tattooing                                                                                                            
   No                                          365(91.2)      38(10.4)       1                  376(94.0)    23(6.1)   1
   Yes                                         35(8.8)        4(11.4)        1.11(0.37-3.32)    24(6.0)      1(4.2)    0.67(0.09-5.16)
  History of liver disease \*\*\*\*                                                                                    
   No                                          373(93.2)      41(11)         1                  387(96.8)    23(5.9)   1
   Yes                                         27(6.8)        1(3.7)         0.31(0.04-2.36)    13(3.2)      1(7.7)    1.32(0.16-10.6)
  Contact with a person having liver disease                                                                           
   No                                          372(93.0)      39(10.5)       1                  379(94.8)    24(6.3)   
   Yes                                         28(7.0)        3(10.7)        1.03(0.30-3.55)    21(5.2)      0         \-

\* having more than one sexual partner; \*\* have ever been diagnosed for sexual transmitted infections (excluding HIV); \*\*\* ever had minor or major surgical operation; \*\*\*\* have ever been diagnosed for liver disease

Discussion
==========

The sero-prevalence of anti-HCV was 10.5% in HIV-positive and 6% in HIV-negative individuals. None of the risk factors included in the analysis significantly increased the odds of HCV exposure. The rate of HIV-HCV co-infection in the present study was higher compared to findings in an earlier report which investigated residents of Addis Ababa (4.5%) \[[@B7]\]. Although we found **a**lower co-infection rate compared with developed nations \[[@B9],[@B10]\], the magnitude of HCV in Ethiopia would become a concern as HIV is more prevalent in our settings.

Despite a weak association, we found a significant difference in rates of anti-HCV positivity between HIV-infected and HIV-non-infected individuals. In agreement, a previous report showed that HIV positive inhabitants in Addis Ababa had about five-fold rate of anti-HCV compared with HIV negative individuals \[[@B7]\]. However, associations between HCV and HIV infections in our settings were not as strong as those reported from industrialized countries where HIV can occur among HCV infected people exclusively \[[@B10],[@B11]\].

Unlike most western countries, risk factors such as repeated transfusions, haemodialysis, or injection drug use are very rare in Ethiopia where transmission of HIV is primarily through heterosexual exposure \[[@B12]\]. While it remains to be fully established, rising evidences point to implications of sexual activity in HCV transmission \[[@B13]\]. Sexual transmission of HCV that might be facilitated by HIV and other STIs has also been reported \[[@B14],[@B15]\]. Therefore, the role of sexual transmission should not be neglected as it may contribute to the higher rate of anti- HCV among HIV-infected individuals.

In the current study, the odds of HCV infection were not shown to be significantly affected by the exposure status of participants to various medical practices. This result contrasts with a finding from Egypt where risk factors including blood transfusion, invasive medical procedures, and frequent injections significantly increased the odds of HCV infection \[[@B16]\]. This may be due to the strength of risk factors varying according to HCV epidemiology in a given geographical area. Moreover, unlike a report from Brazil \[[@B13]\], our investigation as well as a previous study from Egypt \[[@B16]\] showed that the odds of HCV infection was not significantly higher in participants with tattoos or ear piercing compared with those without the respective risk factors in either HIV sero-groups.

HCV infection commonly takes achronic course and studies have reported viraemia persisting in over 80% of infected individuals \[[@B17],[@B18]\]. In the present study, however, HCV-RNA was detected in 9.1% of anti-HCV positive individuals. Such a lower rate of HCV-RNA is unusual and points to a need for further investigation in our settings to confirm or challenge this finding. Factors such as intact immune status \[[@B19]\] and heterosexual HCV transmission \[[@B20]\] were suggested to contribute to varying rates of spontaneous HCV clearance in different geographical regions. In contrast, our study lacked enough power to assess whether factors such as demographic characteristics, routes of transmission, HIV and ART status were influencing rate of HCV clearance.

Findings in this study need to be interpreted in light of its methodological limitations. First, lost participants, who tested HIV positive at the centers and did not register at the ART clinic, may introduce selection bias. Second, there could be a survival bias as a result of deaths occurring among patients with viral hepatic C within the six months following the ART initiation. Third, lack of confirming ELISA positive test results using an immunoblot test might lead to misinterpretation of anti-HCV false positive results as HCV exposures.

In conclusion, HIV-infected individuals had significantly higher positivity rate of anti-HCV although most of them had no sign of viraemia. Hence, with priority given for HIV- infected patients, testing those with anti-HCV for HCV-RNA is important in order to manage HIV-HCV co-infected patients appropriately. Further studies on the epidemiology of HCV infection in our settings are imperative to plan intervention methods systematically.
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